Nilanjan Ghosh

20PUBLICATIONS

132CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursTumour immunologyCardiology (incl. cardiovascular diseases)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (20)

Sort by Publication Date:

|Jul 13, 2026

Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.

|Jun 12, 2026

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

|Apr 25, 2026

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

|Apr 21, 2026

Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

|Feb 24, 2026

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Yucai Wang, Melissa C Larson, Steven R Hwang

|Jan 06, 2026

Juan Pablo Alderuccio, Diva Baggio, Sunwoo Han

Pageof 4

Frequent Collaborators

Natalie S Grover

Michael Wang

Reem Karmali

Yucai Wang

Brad S Kahl

Amitkumar Nitinkumar Mehta

Matthew J Maurer

James R Cerhan

Jonathon B Cohen

Izidore S Lossos

Frequent Collaborators

Natalie S Grover

Michael Wang

Reem Karmali

Yucai Wang